| For FY2028 |
| Share repurchase program authorization | — | — | — | — | — | — | New“up to $1 billion of its outstanding common stock” | Reiterated“up to $1.0 billion of its outstanding common stock” |
| For FY2026 |
| ENHANZE royalty revenue | — | — | — | — | — | — | New“exceed $1 billion” | — |
| Revenue from royalties | — | — | — | — | — | New“$1,130 million to $1,170 million” | Reiterated“$1.130 billion to $1.170 billion, representing growth of 30% to 35% over 2025” | Raised“$1.220 billion to $1.245 billion, representing growth of 41% to 43% over 2025” |
| Royalty Revenue | — | — | — | — | — | New“$1,130 to $1,170 million” | Reiterated“$1.130 to $1.170 billion” | Raised“$1.220 to $1.245 billion” |
| Royalty Revenue Expected YoY Growth | — | — | — | — | — | New“30% to 35%” | — | — |
| Total revenue | — | — | — | — | — | New“$1,710 million to $1,810 million” | Reiterated“$1.710 billion to $1.810 billion, representing growth of 22% to 30% over 2025 total revenue” | Raised“$1.835 billion to $1.910 billion, representing growth of 31% to 37% over 2025 total revenue” |
| Total Revenue Expected YoY Growth | — | — | — | — | — | New“23% to 30%” | — | — |
| Adjusted EBITDA | — | — | — | — | — | New“$1,125 million to $1,205 million” | Reiterated“$1.125 billion to $1.205 billion, representing growth of 71% to 83% over 2025” | Raised“$1.225 billion to $1.280 billion, representing growth of 86% to 95% over 2025” |
| Hypercon and Surf Bio investment included in Adjusted EBITDA and EPS | — | — | — | — | — | New“approximately $60 million” | — | — |
| Non-GAAP diluted earnings per share | — | — | — | — | — | New“$7.75 to $8.25” | Reiterated“$7.75 to $8.25, representing growth of 87% to 99% over 2025” | Raised“$8.65 to $9.00, representing growth of 108% to 117% over 2025” |
| Non-GAAP Diluted EPS | — | — | — | — | — | New“$7.75 to $8.25” | Reiterated“$7.75 to $8.25” | Raised“$8.65 to $9.00” |
| ENHANZE products in development | — | — | — | — | — | — | New“13” | — |
| Expected share repurchases | — | — | — | — | — | — | New“at least $400 million of shares” | Reiterated“at least $400 million of shares” |
| Goal of new SC delivery platform deals | — | — | — | — | — | — | New“three” | — |
| New drug delivery licensing agreements signed | — | — | — | — | — | New“three or more” | — | — |
| New Hypercon and Surf Bio investment included in | — | — | — | — | — | — | New“approximately $60 million” | — |
| Partner programs in development | — | — | — | — | — | New“15” | — | — |
| For FY2025 |
| Revenue from royalties | — | New“$725 million to $750 million” | Raised“$750 million to $785 million” | Raised“$825 million to $860 million, representing growth of 44% to 51% over 2024” | Raised“$850 million to $880 million, representing growth of 49% to 54% over 2024” | — | — | — |
| Royalty Revenue | — | New“$725 to $750 million” | Raised“$750 to $785 million” | Raised“$825 to $860 million” | Raised“$850 to $880 million” | — | — | — |
| Total revenue | — | New“$1,150 million to $1,225 million” | Raised“$1,200 million to $1,280 million” | Raised“$1,275 million to $1,355 million, representing growth of 26% to 33% over 2024 total revenue” | Raised“$1,300 million to $1,375 million, representing growth of 28% to 35% over 2024 total revenue” | — | — | — |
| Adjusted EBITDA | — | New“$755 million to $805 million” | Raised“$790 million to $840 million” | Raised“$865 million to $915 million, representing growth of 37% to 45% over 2024” | Raised“$885 million to $935 million, representing growth of 40% to 48% over 2024” | — | — | — |
| Non-GAAP diluted earnings per share | — | New“$4.95 to $5.35” | Raised“$5.30 to $5.70” | Raised“$6.00 to $6.40, representing growth of 42% to 51% over 2024” | Raised“$6.10 to $6.50, representing growth of 44% to 54% over 2024” | — | — | — |
| Non-GAAP Diluted EPS | — | New“$4.95 to $5.35” | Raised“$5.30 to $5.70” | Raised“$6.00 to $6.40” | Raised“$6.10 to $6.50” | — | — | — |
| For FY2024 |
| Revenue from royalties | New“$550 million to $565 million” | — | — | — | — | — | — | — |
| Royalty Revenue | New“$550 to $565 million” | — | — | — | — | — | — | — |
| Total revenue | New“$970 million to $1,020 million” | — | — | — | — | — | — | — |
| Adjusted EBITDA | New“$595 million to $625 million” | — | — | — | — | — | — | — |
| Non-GAAP diluted earnings per share | New“$4.00 to $4.20” | — | — | — | — | — | — | — |
| Non-GAAP Diluted EPS | New“$4.00 to $4.20” | — | — | — | — | — | — | — |
| No period stated |
| New Accelerated Share Repurchase (ASR) program | — | New“$250 million” | — | — | — | — | — | — |
| Share repurchase | — | — | New“$250 million” | — | — | — | — | — |
| Share repurchase program | — | — | — | — | — | — | New“up to $1 billion” | — |
| Share repurchase tranche | — | — | — | New“$250 million” | — | — | — | — |
HighGravityData